- Home
- CLLS vs RLTY Comparison
CLLS vs RLTY Comparison
Compare CLLS & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CLLS | RLTY |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 245.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLLS | RLTY |
|---|---|---|
| Price | $3.08 | $14.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | 48.3K | ★ 56.0K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $12.90 |
| 52 Week High | $5.48 | $15.97 |
Technical Indicators
Market Signals| Indicator | CLLS | RLTY |
|---|---|---|
| Relative Strength Index (RSI) | 35.29 | 24.71 |
| Support Level | $2.49 | N/A |
| Resistance Level | $3.22 | $15.32 |
| Average True Range (ATR) | 0.21 | 0.24 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 0.00 | 4.93 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.